

1614



CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:

ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231,

ON December 6, 2002

Nora Stein Fernandez
ATTORNEY FOR APPLICANT

December 6, 2002
DATE

TECH CENTER 1600/2900

DEC 20 2002

RECEIVED

1)
Ver
1-24-03

Attorney Docket No.: P50869

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Murphy et al. December 6, 2002
Serial No.: 09/889,904 Group Art Unit: 1614
Filed: January 25, 2000 Examiner: C. Delacroix-Muirheid
For: ANTI-ANDROGENS AND METHODS FOR TREATING DISEASE

Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO COMMUNICATION FROM EXAMINER

Dear Sir:


This Response is made to the Examiner's Communication mailed August 27, 2002. A request for a three-month extension of time accompanies this Response. Claims 9-16 are pending in this application. Reconsideration and withdrawal of the assertion that the Amendment filed June 4, 2002, was unresponsive, are respectfully requested in view of the following remarks.

Original claims 1-8 were canceled and replaced with new claims 9-16. In the Official Action mailed December 20, 2001, the Examiner rejected claims 1-4 and 6 for various reasons under 35 U.S.C. §§112, second paragraph, 102(b) and 102(e). Further, the Examiner stated on page 8 of the Official Action, that claims 5, 7 and 8 would be allowable if rewritten in independent form. In replacing original claims 1-8 with claims 9-16, Applicants did just that. A careful reading of claims 9-16 shows that they are modeled from original claims 5, 7 and 8 by being directed to a method for treating various diseases characterized by androgenic dependency, a method for suppressing testosterone production, and a method for suppressing the production of luteinizing hormone, with the administration of a neurokinin-3

receptor antagonist. Since no rejections were made of these claims, Applicants did not address the rejections of the canceled claims. The newly presented claims are free of the art cited as they were deemed allowable if rewritten in independent format. Therefore, Applicants considered the June 4, 2002, Amendment completely responsive.

In view of the foregoing, favorable consideration of new claims 9-16 and allowance of this application are earnestly solicited.

Respectfully submitted,


Nora Stein-Fernandez
Attorney for Applicants
Registration No. 36,689

GLAXOSMITHKLINE
Corporate Intellectual Property-UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone: (610) 270-5044
Facsimile: (610) 270-5090

n:\nsf\patapps\P50869\Amendment May 2002.doc